TWI669131B - Ｐｃｓｋ９抑制劑用於治療高血脂症的用途 - Google Patents

Ｐｃｓｋ９抑制劑用於治療高血脂症的用途 Download PDF

Info

Publication number
TWI669131B
TWI669131B TW103135495A TW103135495A TWI669131B TW I669131 B TWI669131 B TW I669131B TW 103135495 A TW103135495 A TW 103135495A TW 103135495 A TW103135495 A TW 103135495A TW I669131 B TWI669131 B TW I669131B
Authority
TW
Taiwan
Prior art keywords
patient
patients
ldl
antibody
week
Prior art date
Application number
TW103135495A
Other languages
English (en)
Chinese (zh)
Other versions
TW201605475A (zh
Inventor
馬立 伯可羅
Marie BACCARA-DINET
勞倫斯 伯薩克
Laurence BESSAC
由彌斯 喬哈里
Umesh CHAUDHARI
柯林 漢羅廷
Corinne Hanotin
羅伯特 波狄
Robert C. Pordy
威廉 沙斯艾拉
William J. Sasiela
丹尼爾 舒瓦姆吉普
Daniel A. Schwemmer Gipe
Original Assignee
賽諾菲生物技術公司
Sanofi Biotechnology
再生元醫藥公司
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 賽諾菲生物技術公司, Sanofi Biotechnology, 再生元醫藥公司, Regeneron Pharmaceuticals, Inc. filed Critical 賽諾菲生物技術公司
Publication of TW201605475A publication Critical patent/TW201605475A/zh
Application granted granted Critical
Publication of TWI669131B publication Critical patent/TWI669131B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)
TW103135495A 2013-10-11 2014-10-13 Ｐｃｓｋ９抑制劑用於治療高血脂症的用途 TWI669131B (zh)

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US201361890154P 2013-10-11 2013-10-11
US61/890,154 2013-10-11
US201461923103P 2014-01-02 2014-01-02
US61/923,103 2014-01-02
US201461955514P 2014-03-19 2014-03-19
US61/955,514 2014-03-19
US201462004620P 2014-05-29 2014-05-29
US62/004,620 2014-05-29
US201462025104P 2014-07-16 2014-07-16
US62/025,104 2014-07-16
EP14306221 2014-07-31
EP14306221.4 2014-07-31
US201462054571P 2014-09-24 2014-09-24
US62/054,571 2014-09-24
EP14306584 2014-10-09
EP14306584.5 2014-10-09

Publications (2)

Publication Number Publication Date
TW201605475A TW201605475A (zh) 2016-02-16
TWI669131B true TWI669131B (zh) 2019-08-21

Family

ID=52813751

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103135495A TWI669131B (zh) 2013-10-11 2014-10-13 Ｐｃｓｋ９抑制劑用於治療高血脂症的用途

Country Status (14)

Country Link
US (1) US20150140002A1 (https=)
EP (2) EP3055333B1 (https=)
JP (2) JP6846931B2 (https=)
KR (3) KR20220048051A (https=)
CN (3) CN115192704A (https=)
AU (2) AU2014331754B2 (https=)
CA (1) CA2926942A1 (https=)
EA (1) EA037526B1 (https=)
ES (1) ES2914978T3 (https=)
IL (1) IL244995B (https=)
MX (3) MX373298B (https=)
PL (2) PL3055333T4 (https=)
TW (1) TWI669131B (https=)
WO (1) WO2015054619A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
PL3395836T3 (pl) 2011-01-28 2021-12-13 Sanofi Biotechnology Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2992345T3 (es) 2011-09-16 2024-12-11 Regeneron Pharma Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9)
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US10058630B2 (en) * 2012-10-22 2018-08-28 Concievalve, Llc Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TW202021614A (zh) 2013-06-07 2020-06-16 法商賽諾菲生物技術公司 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
MX2016006226A (es) 2013-11-12 2016-09-07 Sanofi Biotechnology Regimenes de dosificacion para uso con inhibidores de pcsk9.
AU2015289874A1 (en) * 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
PL3169353T3 (pl) 2014-07-16 2020-06-01 Sanofi Biotechnology SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)
EP3283012A4 (en) * 2015-04-15 2018-11-21 Concievalve LLC Devices and methods for inhibiting stenosis, obstruction, or calcification of a native heart valve, stented heart valve or bioprosthesis
CN104861071B (zh) * 2015-04-27 2019-04-12 南京师范大学 针对pcsk9的全人源单克隆抗体的可变区基因及其应用
JP2018523684A (ja) * 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
EP3515950A4 (en) 2016-09-20 2020-10-28 Wuxi Biologics Ireland Limited. NEW ANTI-PCSK9 ANTIBODIES
BR112019020148A2 (pt) 2017-04-13 2020-05-05 Cadila Healthcare Limited peptídeo
US20200131576A1 (en) 2017-04-25 2020-04-30 The Brigham And Women's Hospital, Inc. IL-8, IL-6, IL-1 Beta and TET2 and DNMT3A in Atherosclerosis
CN107090474A (zh) * 2017-05-22 2017-08-25 山东大学 一种腹主动脉瘤疾病动物模型的制备方法
CN109963877B (zh) * 2017-06-14 2023-01-20 江苏恒瑞医药股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
CA3092936A1 (en) * 2018-03-06 2019-09-12 Sanofi Biotechnology Use of pcsk9 inhibitor for reducing cardiovascular risk
IL279363B2 (en) 2018-06-21 2025-12-01 Merck Sharp & Dohme Pcsk9 antagonist compounds
SG11202107614PA (en) 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
AU2020209216A1 (en) 2019-01-18 2021-08-26 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
BR112022009587A2 (pt) * 2019-11-18 2022-08-02 Ad Pharmaceuticals Co Ltd Anticorpo anti-pcsk9 e uso do mesmo
JP2023506732A (ja) * 2019-12-10 2023-02-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ホモ接合型家族性高コレステロール血症を処置するためのｐｃｓｋ９阻害剤の使用
US12577259B2 (en) 2019-12-20 2026-03-17 Merck Sharp & Dohme Llc PCSK9 antagonist compounds
CN114277032A (zh) * 2021-12-31 2022-04-05 华中科技大学同济医学院附属协和医院 一种低密度脂蛋白受体基因突变体及其应用
CN116983434B (zh) * 2023-09-28 2024-03-15 康霖生物科技（杭州）有限公司 用于基因治疗的核酸构建体及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012101253A1 (en) * 2011-01-28 2012-08-02 Sanofi Pharmaceutical compositions comprising human antibodies to pcsk9
US20130064825A1 (en) * 2011-05-10 2013-03-14 Amgen Inc. Methods of treating or preventing cholesterol related disorders
US20130064834A1 (en) * 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8357371B2 (en) * 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
US20130006482A1 (en) * 2011-06-30 2013-01-03 Ramadev Burigsay Hukkeri Guidance system for a mobile machine
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2992345T3 (es) * 2011-09-16 2024-12-11 Regeneron Pharma Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9)
TWI682780B (zh) * 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130064834A1 (en) * 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
WO2012101253A1 (en) * 2011-01-28 2012-08-02 Sanofi Pharmaceutical compositions comprising human antibodies to pcsk9
US20130064825A1 (en) * 2011-05-10 2013-03-14 Amgen Inc. Methods of treating or preventing cholesterol related disorders

Also Published As

Publication number Publication date
JP2019214594A (ja) 2019-12-19
WO2015054619A3 (en) 2015-06-04
EA201690754A1 (ru) 2016-10-31
PL3055333T4 (pl) 2020-07-27
AU2014331754A1 (en) 2016-05-26
CN115154599A (zh) 2022-10-11
TW201605475A (zh) 2016-02-16
ES2914978T3 (es) 2022-06-20
CN115192704A (zh) 2022-10-18
PL3689913T3 (pl) 2022-07-04
EP3689913B1 (en) 2022-03-23
US20150140002A1 (en) 2015-05-21
AU2020203636A1 (en) 2020-06-25
EP3689913A1 (en) 2020-08-05
MX2022013172A (es) 2022-11-30
IL244995B (en) 2019-12-31
EP3055333A2 (en) 2016-08-17
WO2015054619A8 (en) 2016-03-31
AU2014331754B2 (en) 2020-06-18
CA2926942A1 (en) 2015-04-16
PL3055333T3 (pl) 2020-06-01
KR20160062166A (ko) 2016-06-01
KR20220048051A (ko) 2022-04-19
EA037526B1 (ru) 2021-04-08
WO2015054619A2 (en) 2015-04-16
JP6994484B2 (ja) 2022-02-04
CN105814085A (zh) 2016-07-27
EP3055333B1 (en) 2019-12-04
KR20230119045A (ko) 2023-08-14
AU2020203636B2 (en) 2023-05-18
JP2016538248A (ja) 2016-12-08
IL244995A0 (en) 2016-05-31
MX2020004023A (es) 2020-08-13
MX373298B (es) 2020-05-20
JP6846931B2 (ja) 2021-03-24
MX2016004580A (es) 2016-12-08

Similar Documents

Publication Publication Date Title
TWI669131B (zh) Ｐｃｓｋ９抑制劑用於治療高血脂症的用途
JP7467538B2 (ja) ヘテロ接合性家族性高コレステロール血症（ｈｅＦＨ）を有する患者を処置するための方法
US12606638B2 (en) Dosing regimens for use with PCSK9 inhibitors
JP6912374B2 (ja) 高コレステロール血症を有する高心血管リスク患者を処置するための方法
KR20160132459A (ko) 심혈관 위험을 감소시키는 방법
TWI723478B (zh) Ｐｃｓｋ９抑制劑用於治療高血脂症的用途
HK40033729A (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
HK40033729B (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
HK1227890A1 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
HK1227890B (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
EA051213B1 (ru) Применение ингибитора pcsk9 для лечения гиперлипидемии